Following potential billion dollar J&J deal, RNA processing biotech Remix returns with fresh financing

A few months ago, Remix Therapeutics penned a deal with Johnson & Johnson that could end up being worth more than $1 billion dollars down the line.

Now, Remix is back with $70 million in new financing as it continues to develop its RNA processing technology, the company announced this…